Therapeutic strategies based on the biological function of BAP1 have been developed and evaluated for tumor patients harboring BAP1 deficiencies or alterations [38], such as histone deacetylase (HDAC) inhibitor, EZH2 inhibitor and PARP inhibitor [39–42]. Here, HDAC9 is linked to neoplasm.